Menu
Back to Journals » Drug Design, Development and Therapy » Is CADD ready to take a leap in the light of AI? Where are we?
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4136)
- Volume 18, 2024 (97)
- Volume 17, 2023 (283)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Journal Articles:
- Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System (1)
- Using Innovative Drug Delivery Systems to Improve the Efficacy and Applicability of Poorly Water-soluble Drugs (1)
- Advances in design and development of ophthalmic drugs (5)
- A cross-sectional survey on heart failure from China: disease burden and management (3)
- Ten Years of Biosimilars in Europe (4)
Is CADD ready to take a leap in the light of AI? Where are we?
Artificial intelligence (AI) in a research domain represents the theory and the computer technology development that helps to model the physical reality of the phenomenon under study. AI is capable of solving complex problems with higher accuracy and efficiency, such as robust language models like GPT, 3D protein model prediction tools like AlphaFold, and defeating champions in a board game like AlphaGo etc. The success of AI is well appreciated in our day-to-day life as well as in corporate businesses. However, its impact on computer aided drug design (CADD) is still awaited.